1
|
Parciak T, Geys L, Helme A, van der Mei I, Hillert J, Schmidt H, Salter A, Zakaria M, Middleton R, Stahmann A, Dobay P, Hernandez Martinez-Lapiscina E, Iaffaldano P, Plueschke K, Rojas JI, Sabidó M, Magyari M, van der Walt A, Arickx F, Comi G, Peeters LM. Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force. Mult Scler 2024; 30:396-418. [PMID: 38140852 PMCID: PMC10935622 DOI: 10.1177/13524585231216004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 10/09/2023] [Accepted: 10/23/2023] [Indexed: 12/24/2023]
Abstract
BACKGROUND As of September 2022, there was no globally recommended set of core data elements for use in multiple sclerosis (MS) healthcare and research. As a result, data harmonisation across observational data sources and scientific collaboration is limited. OBJECTIVES To define and agree upon a core dataset for real-world data (RWD) in MS from observational registries and cohorts. METHODS A three-phase process approach was conducted combining a landscaping exercise with dedicated discussions within a global multi-stakeholder task force consisting of 20 experts in the field of MS and its RWD to define the Core Dataset. RESULTS A core dataset for MS consisting of 44 variables in eight categories was translated into a data dictionary that has been published and disseminated for emerging and existing registries and cohorts to use. Categories include variables on demographics and comorbidities (patient-specific data), disease history, disease status, relapses, magnetic resonance imaging (MRI) and treatment data (disease-specific data). CONCLUSION The MS Data Alliance Core Dataset guides emerging registries in their dataset definitions and speeds up and supports harmonisation across registries and initiatives. The straight-forward, time-efficient process using a dedicated global multi-stakeholder task force has proven to be effective to define a concise core dataset.
Collapse
Affiliation(s)
- Tina Parciak
- University MS Center (UMSC), Hasselt-Pelt, Belgium
- UHasselt, Biomedical Research Institute (BIOMED), Diepenbeek, Belgium
- UHasselt, Data Science Institute (DSI), Diepenbeek, Belgium
| | - Lotte Geys
- University MS Center (UMSC), Hasselt-Pelt, Belgium
- UHasselt, Biomedical Research Institute (BIOMED), Diepenbeek, Belgium
- UHasselt, Data Science Institute (DSI), Diepenbeek, Belgium
| | - Anne Helme
- Multiple Sclerosis International Federation, London, UK
| | - Ingrid van der Mei
- Menzies Institute for Medical Research, University of Tasmania, The Australian MS longitudinal study (AMSLS), Hobart, TAS, Australia
| | - Jan Hillert
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Hollie Schmidt
- Accelerated Cure Project, iConquerMS People-Powered Research Network, Waltham, MA, USA
| | - Amber Salter
- Section on Statistical Planning and Analysis, UT Southwestern Medical Center, NARCOMS Registry, COViMS Registry, Dallas, TX, USA
| | - Magd Zakaria
- Department of Neurology, Ain Shams University, Cairo, Egypt
| | - Rodden Middleton
- Population Data Science, Swansea University Medical School, Swansea, UK
| | - Alexander Stahmann
- German MS Register by the German MS Society, MS Research and Project Development gGmbH (MSFP), Hanover, Germany
| | | | - Elena Hernandez Martinez-Lapiscina
- Office of Therapies for Neurological and Psychiatric Disorders (H-NEU), Human Medicines (H-Division), European Medicines Agency, Amsterdam, The Netherlands
| | - Pietro Iaffaldano
- Department of Translational Biomedicine and Neurosciences (DiBraiN), Università degli Studi di Bari Aldo Moro, Italian MS registry, Bari, Italy
| | - Kelly Plueschke
- Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands
| | - Juan I Rojas
- Neurology Department, Hospital Universitario de CEMIC, RelevarEM, Buenos Aires, Argentina
| | - Meritxell Sabidó
- Department of Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany
| | - Melinda Magyari
- Danish Multiple Sclerosis Registry and Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Denmark
| | - Anneke van der Walt
- Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Francis Arickx
- National Institute for Health and Disability Insurance, Brussels, Belgium
| | - Giancarlo Comi
- Department of Rehabilitation Neurosciences, Casa di Cura Igea, Milan, Italy
| | - Liesbet M Peeters
- University MS Center (UMSC), Hasselt-Pelt, Belgium
- UHasselt, Biomedical Research Institute (BIOMED), Diepenbeek, Belgium
- UHasselt, Data Science Institute (DSI), Diepenbeek, Belgium
| |
Collapse
|
2
|
Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal. Mult Scler Relat Disord 2021; 54:103091. [PMID: 34246020 DOI: 10.1016/j.msard.2021.103091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 05/27/2021] [Accepted: 06/13/2021] [Indexed: 11/20/2022]
Abstract
BACKGROUND Several disease-modifying therapies (DMTs) have emerged in the last two decades for the treatment of multiple sclerosis (MS). The increasing use of these therapies has enhanced the need to study its impact on long-term disease progression and on the natural history of MS. This study aimed to characterize a Portuguese MS patient cohort in what concerns the natural history of disease by exploring differences throughout 3 decades. METHODS Longitudinal, retrospective, non-interventional study. Patients aged ≥ 18 years old, with confirmed diagnosis of relapsing-remitting MS (RRMS), were included. Biodemographic and clinical characteristics (MS diagnosis, patient follow-up, relapses, treatment, and exams) were assessed and compared according to the first appointment date throughout 10-year spans (1987-1996; 1997-2006; 2007-2016). RESULTS 548 patients were included in this analysis. Significant differences were observed between decades for evoked potential (EP) and cerebrospinal fluid (CSF) exams conducted at diagnosis, the first with less expression on the last decade; the median number of relapses per year (higher in the subgroup 07-16); EDSS at baseline and at last appointment (both higher in the subgroup 87-96); and the percentage of patients achieving EDSS 3.0 and EDSS 6.0 (increased in the subgroup 87-96). Additionally, time from diagnosis to first treatment was significantly lower in patients from the most recent decade, and a greater percentage of such patients, compared to the other two subgroups, was, at last appointment, under a second line DMT. CONCLUSION In general, our study reflects findings from longitudinal studies on MS progression already published in the literature. In recent years, the growing number of more effective DMTs, along with earlier disease detection, and improvements in access to healthcare appear to have had a positive impact on patients' access to treatment and, consequently, disease progression. Additional studies, with increased follow up time, are needed to further investigate the effect of treatment improvement in the natural history of MS.
Collapse
|
3
|
Patti F, Visconti A, Capacchione A, Roy S, Trojano M. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord 2020; 13:1756286420922685. [PMID: 32587633 PMCID: PMC7294475 DOI: 10.1177/1756286420922685] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Background The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. Methods Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan-Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model. Results Time span under observation in the Italian MS Registry was 1-137 (median 80.3) months. In the total Italian patient population (n = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5-39.5) months. Conclusion CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.
Collapse
Affiliation(s)
- Francesco Patti
- Azienda Ospedaliera-Universitaria, "Policlinico Vittorio Emanuele", Catania via Santa Sofia 78, Catania, 95123, Italy
| | - Andrea Visconti
- Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany
| | - Antonio Capacchione
- Merck Serono S.p.A., Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany
| | - Sanjeev Roy
- Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany
| | - Maria Trojano
- Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy
| | | |
Collapse
|
4
|
Sheykhotayefeh M, Safdari R, Ghazisaeedi M, Khademi SH, Seyed Farajolah SS, Maserat E, Jebraeily M, Torabi V. Development of a Minimum Data Set (MDS) for C-Section Anesthesia Information Management System (AIMS). Anesth Pain Med 2017; 7:e44132. [PMID: 28824861 PMCID: PMC5556329 DOI: 10.5812/aapm.44132] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2016] [Revised: 12/24/2016] [Accepted: 12/25/2016] [Indexed: 11/17/2022] Open
Abstract
Background Caesarean section, also known as C-section, is a very common procedure in the world. Minimum data set (MDS) is defined as a set of data elements holding information regarding a series of target entities to provide a basis for planning, management, and performance evaluation. MDS has found a great use in health care information systems. Also, it can be considered as a basis for medical information management and has shown a great potential for contributing to the provision of high quality care and disease control measures. Objectives The principal aim of this research was to determine MDS and required capabilities for Anesthesia information management system (AIMS) in C-section in Iran. Methods Data items collected from several selected AIMS were studied to establish an initial set of data. The population of this study composed of 115 anesthesiologists was asked to review the proposed data elements and score them in order of importance by using a five-point Likert scale. The items scored as important or highly important by at least 75% of the experts were included in the final list of minimum data set. Results Overall 8 classes of data (consisted of 81 key data elements) were determined as final set. Also, the most important required capabilities were related to airway management and hypertension and hypotension management. Conclusions In the development of information system (IS) based on MDS and identification, because of the broad involvement of users, IS capabilities must focus on the users’ needs to form a successful system. Therefore, it is essential to assess MDS watchfully by considering the planned uses of data. Also, IS should have essential capabilities to meet the needs of its users.
Collapse
Affiliation(s)
- Mostafa Sheykhotayefeh
- Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
- Department of Health Information Technology, School of Allied Medical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
| | - Reza Safdari
- Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
- Corresponding authors: Reza Safdari, Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98-2188985671, E-mail: ; Marjan Ghazisaeedi, Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. E-mail:
| | - Marjan Ghazisaeedi
- Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
- Corresponding authors: Reza Safdari, Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98-2188985671, E-mail: ; Marjan Ghazisaeedi, Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. E-mail:
| | - Seyed Hossein Khademi
- Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran
- Department of Anesthesiology, School of Allied Medical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
| | - Seyedeh Sedigheh Seyed Farajolah
- Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
| | - Elham Maserat
- Medical Informatics Faculty, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Mohamad Jebraeily
- Department of Health Information Technology, Urmia University of Medical Sciences, Urmia, Iran
| | - Vahid Torabi
- Department of Parasitology, School of Health, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
Ajami S, Maghsoudlorad AA. The Role of Information Systems to Manage Cerebral Palsy. IRANIAN JOURNAL OF CHILD NEUROLOGY 2016; 10:1-9. [PMID: 27247578 PMCID: PMC4885149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Revised: 04/13/2015] [Accepted: 04/14/2015] [Indexed: 11/30/2022]
Abstract
Objective In healthcare system, it is necessary to have exact and accurate information in order to address health care needs and requirements of society members as well as expectations of policy makers, planners and decision makers. The aim of this narrative review article was to explain the role of information systems in cerebral palsy management and identify the advantages and barriers to the development of cerebral palsy registry system. Data were collected using databases such as of Science Direct, PubMed, Proquest, Springer, and SID (Scientific Information Database). Overall, 65 sources were selected. One of the biggest challenges for children with physical and motor disabilities in rehabilitation center is access to a system, which provides a comprehensive data set reflecting all information on a patient's care. Thus, data and information management in children with physical and motor disability such as cerebral palsy facilitates access to data and cerebral palsy data comparison as well as the monitoring incidence rate of cerebral palsy, enhancing health care quality; however, there are always numerous barriers to establish the system. One of the ways to overcome these problems is the establishment of a standard framework of minimum data sets and exact definition of its data components. Reliable standards in the use of applications as well as user-friendly software will ensure patients' data extraction and registration.
Collapse
Affiliation(s)
- Sima Ajami
- Department of Health Information Technology and Management, School of Medical Management and Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Ali Akbar Maghsoudlorad
- Department of Health Information Technology and Management, School of Medical Management and Information Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|